Keywords: Japan, NHI drug pricing, Pharma R&D, FPMAJ
Japan’s drug pricing reform will trigger industry reorganization, claims FPMAJ chief; Pharma R&D spend
Article | 18 January 2010
The Japanese National Health Insurance pricing reform that is due to take effect in April will trigger major reform in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
